Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy

Nimrat Kaur

doi:10.36948/ijfmr.2024.v06i01.11465

Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy

Author(s)	Nimrat Kaur
Country	India
Abstract	Cancer's profound medical challenge underscores the urgency for innovative solutions. Contemporary immunotherapy has formidable challenges dealing with immune evasion, complex tumor microenvironments (TME), and checkpoint inhibitors. Improvements to immunotherapy have been made through genome editing for which the Cas9 system is utilized, but its reliance on DNA repair mechanisms coupled with elevated off-target effects presents limitations. One alternative approach to gene editing is the modulation of gene expression using dCas9 and associated effectors. An advantage is dCas9's non-cleaving nature which reduces the chance of off-target effects and avoids permanent changes to the genome, offering enhanced safety as a gene modulation tool. We reviewed ongoing studies and clinical trials on immunotherapy, gene expression, and dCas9 to address whether gene modulation via dCas9 could be a viable solution to improve gene therapy. In (one/a few) studies found that dCas9's adoption decreases off-target effects, heightening its appeal for improving immunotherapy compared to traditional gene editing with Cas9. Therefore, integrating dCas9 in suppressing key target genes, dcas9 with effector domains or epigenetic modifiers could prove as a pivotal strategy, enabling precise gene regulation and epigenetic modification. Specifically, transcriptional activators like VP64 and repressors like KRAB exhibit the potential to modulate target genes when used with dcas9. Acknowledging limitations, such as mutations affecting gene regulation, this study underscores the transformative potential of dCas9-mediated epigenetic regulation in reshaping the landscape of cancer treatment and calls for further investigation to unlock its full therapeutic potential.
Keywords	Epigenetics, dcas9, Cancer, effector domains, immunotherapy
Field	Biology > Genetics / Molecular
Published In	Volume 6, Issue 1, January-February 2024
Published On	2024-01-11
Cite This	Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy - Nimrat Kaur - IJFMR Volume 6, Issue 1, January-February 2024. DOI 10.36948/ijfmr.2024.v06i01.11465
DOI	https://doi.org/10.36948/ijfmr.2024.v06i01.11465
Short DOI	https://doi.org/gtfmvc

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Unlocking the potential of dCas9: Epigenetic targeting in cancer immunotherapy

Share this